What is HC Wainwright’s Estimate for BioNTech Q1 Earnings?

BioNTech SE (NASDAQ:BNTX) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of BioNTech in a research note issued on Thursday, June 5th. HC Wainwright analyst R. Burns expects that the company will earn ($2.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $145.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.33) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at $0.90 EPS and FY2026 earnings at ($4.46) EPS.

A number of other analysts also recently weighed in on BNTX. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday. Morgan Stanley cut their price target on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Leerink Partners set a $112.00 target price on BioNTech in a report on Monday, June 2nd. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. reduced their price target on BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.25.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $106.89 on Monday. The company has a market capitalization of $25.70 billion, a price-to-earnings ratio of -50.90 and a beta of 1.29. The firm’s 50 day simple moving average is $99.87 and its 200 day simple moving average is $108.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.90 EPS.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently modified their holdings of the company. Banque Cantonale Vaudoise bought a new stake in BioNTech during the first quarter worth $36,000. Jones Financial Companies Lllp lifted its holdings in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new stake in BioNTech during the 4th quarter worth about $90,000. Finally, Banque Transatlantique SA bought a new stake in shares of BioNTech during the 1st quarter valued at about $80,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.